The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes



Davies, MJ, Baldry, EL, Bodicoat, DH, Chatterjee, S, Edwardson, CL, Gray, LJ, Khunti, K, Sargeant, JA, Stensel, DJ, Webb, DR
et al (show 4 more authors) (2020) The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes. .

[img] Text
EASD abstract V3 24 3 2020.docx - Accepted Version
Access to this file is embargoed until 1 September 2021.

Download (29kB)
Item Type: Conference or Workshop Item (Unspecified)
Depositing User: Symplectic Admin
Date Deposited: 15 Oct 2020 08:28
Last Modified: 02 Apr 2021 08:27
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3103645